BUILDING STAKEHOLDER ENGAGEMENT THROUGH EAPs Download our guide on leveraging Early Access Programs to engage healthcare professionals, payers, and empower eligible patients with early access to innovative therapies. Gain valuable insights, contribute to real-world evidence, [...]
Clinical Trial Services WEP Clinical is the leading Pharma Services Provider partnering with Sponsors from pre-clinical through the start of commercialization.It is our mission to ensure every patient has access to treatment, be it through [...]
International Recognition Procedure From January 2024, the MHRA is adopting the International Recognition Procedure, reflecting a strategic pivot towards an independent and collaborative regulatory framework for swift and secure drug authorizations in the UK. Our [...]
Voluntary Scheme for Branded Medicines, Pricing, Access and Growth (VPAG) The new VPAG scheme is due to come in effect in January 2024 lasting for 5 years. The scheme, which has been agreed between the [...]
WEP News All News20232021202220202019201820172016WEP CLINICAL HAS PARTNERED WITH PLUSULTRA PHARMA TO SUPPLY HYFTOR® TO PATIENTS IN EU/EEA COUNTRIES (WITH THE EXCEPTION OF GERMANY)1st December 2023/Read More2023WEP CLINICAL ANNOUNCES PARTNERSHIP WITH GERON CORPORATION FOR AN EXPANDED [...]
Managing patient requests for Your investigational medicines Expanded Access Programs (EAPs) allow companies to provide their investigational medicines to patients outside of the clinical trial setting, to fulfil unmet clinical needs.WEP has put together a [...]
Thank you for your interest in WEP Please see the resource below and check your inbox for the PDF version Managing patient requests for Your investigational medicines Are you receiving unsolicited requests for your phase [...]
Complete the form below and we will reach out to confirm your booking US +1 919-694-5088INFO@WEPCLINICAL.COM 951 AVIATION PARKWAY, SUITE 200, MORRISVILLE, NC, 27560 UK +44 208 004 8185INFO@WEPCLINICAL.COM CHISWICK TOWER, 389 CHISWICK HIGH ROAD, 14TH [...]
Navigating the Future of EU Joint Health Technology Assessments With the Health Technology Assessment (HTA) landscape undergoing transformation in January 2025, it's essential to prepare your pipeline for what lies ahead. Our Market Access team [...]
Early Access Programs allow patients and physicians to use investigational (pre-approval) drugs outside the clinical trial setting. They are often referred to as Expanded Access Programs (EAPs), Compassionate Use Programs (CUPs), or Managed Access [...]
